



Investor service announcement no. 4/2013

To: NASDAQ OMX Copenhagen

Hørsholm, Denmark, 8 November, 2013

**Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Interim Report for third Quarter 2013 – results from 1 January to 30 September, 2013**

Veloxis Pharmaceuticals A/S (OMX: VELO) will announce the Interim Report for the third Quarter 2013 on Wednesday 13 November, 2013 after 05:00 PM CET. Veloxis' Management will host an accompanying conference call to discuss the financial results on Thursday 14 November, 2013 at 4:00 PM CET (Denmark); 3:00 PM GMT (London), 10:00 AM EST (New York),

To access the live conference call, please dial one of the following numbers:

+45 32 72 80 18 (Denmark)

+44 (0) 1452 555 131 (UK)

+1 866 682 8490 (USA)

Access code 96780245

Following the conference call, a recording will be available on the company's website <http://www.veloxis.com>.

**For more information, please contact:**

John D. Weinberg  
EVP, Chief Commercial Officer  
Mobile: +1 908 304 3389  
Email: [jdw@veloxis.com](mailto:jdw@veloxis.com)

Johnny Stilou  
EVP, Chief Financial Officer  
Mobile: +45 21 227 227  
Email: [jst@veloxis.com](mailto:jst@veloxis.com)

**Veloxis Pharmaceuticals A/S (VELO)**

Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. The company's lead product candidate is LCP-Tacro™ for immunosuppression, specifically organ transplantation. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability at low scale up costs. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market that is commercialized through partner Santarus, Inc. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.

For further information, please visit [www.veloxis.com](http://www.veloxis.com).